Oral Anticoagulant Treatment with and without Aspirin

• References

• 1 Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127-129
• 2 Altman R, Rouvier J, Gurfinkel E, D’Ortencio O, Manzanel R, de la Fuente L, Favaloro RG. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431
• 3 Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-1541
• 4 Isom OW, Spencer FC, Glassman E, Teiko P, Boyd AD, Cunningham JN, Reed GE. Long-tenn results in 1375 patients undergoing valve replacement with the Starr-Edwards cloth-covered steel ball prosthesis. Ann Surg 1977; 186: 310-323
• 5 Dale J, Myhre E, Storstein O, Stormorken H. Efskind L. Prevention of arterial thromboembolism with acetilsalicylic acid:a controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94: 101-111
• 6 Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M. Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-529
• 7 Cannegieter SC, Rosendaal FR. Briet E. Thromboembolic and bleeding complications inpatients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641
• 8 St John Sutton MG, Miller GAH, Oldershaw PJ, Paneth M. Anticoagulants and the Bjork-Shiley prosthesis. Experience of 390 patients. Brit Heart J. 1978; 40: 558-562
• 9 Brott WH, Zajtchuk R, Bowen TE, Davia J, Green DC. Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis. J Thorac Cardiovas Surg. 1982; 81: 632-635
• 10 Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, NG RP, Tse TF. Warfarin versus dipyrydamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059-1063
• 11 Harlan BJ, Smeloff EA, Miller Jr GE, Kelly Jr PB, Junod FL, Ross KA, Shankar KG. Performance of the Smeloff aortic valve beyond ten years. J Thorac Cardiovasc Surg 1986; 91: 86-91
• 12 Hartz RS, LoCicero J, Kucich V, DeBoer A, O’Mara S, Meyers SN, Michaelis LL. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thoraci Cardiovasc Surg 1986; 92: 684-690
• 13 Czer LSC, Matlof f, Chaux A, De Robertis M, Stewart ME, Gray RJ. The St Jude valve: Analysis of thromboembolism, warfarin-related hemorrhage, and survival. Am Heart J 1987; 114: 389-397
• 14 Myers ML, Lawrie GM, Crawford ES, Howell JF, Morris GC, Glaeser DH, De Bakwy ME. The St. Jude valve prosthesis analysis of the clinical results in 815 implants and the need for systemic anticoagulation. JACC 1989; 13: 57-62
• 15 Nair Ch K, Mohiuddin SM, Hilleman DE, Schultz R, Bailey RT, Cook CT, Sketch MH. Ten-year results with the St. Jude Medical prosthesis. Am J Cardiol 1990; 65: 217-225
• 16 Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102: 445S-455S
• 17 Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432
• 18 Turpie AGG, Gunstensen J, Hirsh J, Nelson H. Gent M. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242-1245
• 19 Cortina JM, Martinell J, Artiz V, Fraile J, Rabago G. Comparative clinical results with Omniscience (STM 1), Medtronic-Hall, and Bjork-Shiley convex- concave (70 degrees) prostheses in mitral valve replacement. J Thorac Cardiovasc Surg 1986; 91: 174-183
• 20 Kinsley RH, Antunes MJ, Colsen PR. St. Jude Medical valve replacement. An evaluation of valve performance. J Thorac Cardiovasc Surg 1986; 92: 349-360
• 21 Kopf GS, Hammond GL, Geha AS, Elefteriades J, Hashim SW. Long-term performance of the St. Jude Medical valve: low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 1987; 76 III III132-III136
• 22 Smith JA, Westlake GW, Mullerworth MH, Skillington PD, Tatoulis J. Excellent long-term results of cardiac valve replacement with the St. Jude Medical valve prosthesis. Circulation 1993; 88 (02) 49-54
• 23 Borkon AM, Soule LM, Baughman KL, Aoun H, Baumgartner WA, Gardner TJ, Watkins Jr L, Gott VL, Reitz BA. Comparative analysis of mechanical and bioprosthetic valves after aortic valve replacement. J Thorac Cardiovasc Surg 1987; 94: 20-33
• 24 Carrier M, Martineu JP, Bonan R, Pelletier LC. Clinical and hemodynamic assessment of the Omniscience prosthetic heart valve. J Throrac Cardiovasc Surg 1987; 93: 300-307
• 25 Burckhardt D, Striebel D, Vogt S, Hoffmann A, Roth J, Weiss Ph, Kiowski W, Pfisterer M, Burkart F, Althaus U, Goy JJ, Sadeghi H, Gradel E. Heart valve replacement with St. Jude Medical valve prosthesis. Long-term experience in 743 patients in Switzerland. Circulation 1998; 78 (01) 118-124
• 26 Butchart EG, Lewis PA, Grunkemeier GL, Kulatilake N, Breckenridge IM. Low risk of thrombosis and serious embolic events despite low intensity anticoagulation. Experience with 1,004 Medtronic Hall valves. Circulation 1988; 78 (01) I66-177
• 27 Lindblom D. Long-term clinical results after mitral valve replacement with the Björk-Shiley prosthesis. J Thorac Cardiovasc Surg 1988; 95: 321-333
• 28 The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991; 338: 1345-1349
• 29 The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266
• 30 Gurfinkel E, Altman R, Scazziota A, Rouvier J, Mautner B. Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina. Br Heart J 1994; 71: 151-155
• 31 Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engl J Med 1992; 327: 192-194
• 32 Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation 1994; 89: 81-88
• 33 The Sixty Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980; ii: 989-994
• 34 Smith P, Amesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152
• 35 Anticoagulants in the secondary prevention of events in coronary thrombosis (ASPECT) research group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994; 343: 499-503
• 36 Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81-106
• 37 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537